1.1. Liu G, Franssen E, Fitch MI et al. Patients preferences for oral vs. intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-5.2.2. Binet S, Chaineau E, Fellous A et al. Immunofluorescence study of the action of navelbine, vincristine on mitotic and axonal microtubules. Int J Cancer 1990; 46: 262-6.3.3. Marty M, Fumoleau P, Adenis A et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001; 12: 1643-9.4.4. Varoli P, Nguyen L, Tranchard B et al. A simultaneous oral/intravenous population pharmacokinetics model for vinorelbine. Eur J Clin Pharmacol 2002; 58: 467-76.5.5. Dipierre A, Chastang Cl, Quoix E et al. Vinorelbine versus vinorelbine plus cisplatin in advanced NSCLC: a randomized trial. Ann of Oncol 1994; 5: 37-42.6.6. Le Chevalier T. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin vs. vinorelbine alone in advanced non-small cell lung cancer: a results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12 (12): 360-7.7.7. Crawford J, O'Rourke M, Schiller JH et al. Randomized trial of the vinorelbine compared with fluorouracil plus leucovorin on patients with stage IV NSCLC. J Clin Oncol 1996; 14 (10): 2774-84.8.8. Fumoleau P, Delgao FM, Delozier T et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1993; 11: 1245-332.9.9. Garcia-Gonde J et al. Phase II trial of weekly in vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994; 5: 854-7.10.10. Bruno S, Lira-Peurto V, Mickiewicz F et al. Phase II trial with navelbine in the treatment of advanced breast cancer patients. Ann Oncol 1992; 3 (1): 126-9.11.11. Weber B, Vogel C, Jones et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995; 13: 2722-30.12.12. Romero A, Rabinovitch MG, Vallero C. Vinorelbine as first line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12: 336-41.13.13. Terenziani M, Demicheli R, Brambilla C et al. Vinorelbine: an active, non-cross-resistant drug in advanced breast cancer - results from a phase II study. Breast Cancer Research Treatment 1996; 39: 285-91.14.14. Vogel C, O'Rourke M, Winer et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years old. Ann Oncol 1999; 10: 397-402.15.15. Gligorov J, Beerblock K, Selle F et al. Capecitabine and oral vinorelbine in metastatic breast cancer: preliminary experience. Proc Am Soc Clin Oncol 2003; 22. Abstr. 351.16.16. Anton A, Lluch A, Casado A et al. Phase I-II study of oral vinorelbine (NVBO) and capecitabine (X) in metastatic breast cancer (MBC): results of the phase I trial. J Clin Oncol 2008; 26 (15s): 67s. Abstr. 1105.17.17. Gil-Delgado M, Rocher M, Boostandoost E, Khayat D. First step of oral vinorelbine and capecitabine combination in advanced breast cancer patients: feasibility study. J Clin Oncol 2008; 26: 1135 (15s).18.18. Delcambre C, Veyret C, Levy C et al. A phase I-II study of capecitabine (Xeloda®) combined with oral vinorelbine as first- or second-line therapy on locally advanced or metastatic breast cancer (MBC). Proc San Antonio Breast Cancer Symposium 2005. Abstr. 1081.19.19. Kellokumpu-Lehtinen PL, Sunela K, Lehtinen I et al. Finished Breast Cancer Group. A phase I study of an all oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 2006; 17: 401-5.20.20. Nole F, Catania C, Sanna G et al. Dose-finding and pharmacokinetic study of an all oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006; 17: 322-9.21.21. Finek J, Holubec L Jr, Svoboda T et al. A phase II trial of oral vinorelbine and capecitabine in antracycline pretreated patients with metastatic breast cancer. Anticancer Res 2009; 29 (2): 667-70.22.22. Nole F, Grivellari D, Mattioli R et al. Phase II study of an all oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2009; 64 (4): 673-80.23.23. Tubiana-Mathieu N, Bougnoux P, Becquart D et al. All oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an international phase II trial. Br J Cancer 2009; 101 (2): 232-7.24.24. Jones A, O'Brien M, Sommer H et al. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 2010; 65 (4): 755-63.25.25. Kowalski DM, Krzakowski MJ, Zajda K et al. Oral vinorelbine (NVBo) at 3-weekly flat-dose intakes (FDI) as single agent or with cisplatin (CDDP) concomitantly with thoracic radiotherapy (RT) in stage III NSCLC: Escalation-dose phase I trial results. ASCO Meeting. Abstr. 2011, abstr. 7045.26.26. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.